Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5368058 | 0.90 | SMN1; SMN2 (0.52) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5370473 | 0.86 | ALDH1A1 (0.43) | MAPTKMT2ASMN1; SMN2ALDH1A1MAPK1 | |
| SCHEMBL5366028 | 0.82 | MAPT (0.54) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5366036 | 0.82 | MAPT (0.54) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5368271 | 0.77 | MAPK1 (0.53) | MAPTKMT2ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5724310 | 0.76 | MAPT (0.50) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5369496 | 0.76 | MEN1 (0.50) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5364442 | 0.76 | MEN1 (0.50) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5724315 | 0.76 | MAPT (0.52) | MAPTMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL5370527 | 0.75 | TSHR (0.46) | ALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294716-B2 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALLERGAN, INC. (US) | 2007-11-13 | — | — | US | disclosed |
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038076-A1 | Process for preparing isomerically pure prodrugs of proton pump inhibitors | SI, ATP6AP1, HRH2 | MAPT 4649/4885MEN1 2438/4885KMT2A 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.